Tralokinumab

Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of tralokinumab for the treatment of atopic dermatitis.

Nearly half of patients with head and neck atopic dermatitis who were treated with tralokinumab reported disease clearance after 9 months, according to a presentation at the European Academy of Dermatology and Venereology Congress.

Tralokinumab improved epidermal pathology, reduced inflammation and changed significant skin biomarkers in patients with atopic dermatitis, according to a study published in The European Journal of Allergy and Clinical Immunology.

The FDA has approved a single-dose autoinjector for Adbry, LEO Pharma announced in a press release.

MIAMI BEACH, Fla. — Patients with atopic dermatitis resistant to systemic therapy, including dupilumab, may benefit from tralokinumab treatment, according to a poster presentation here.

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the interleukin-13 blocker tralokinumab from the Maui Derm 2024 meeting, centering around research into longer-term use of the treatment for atopic dermatitis.

The FDA approved an expanded indication for tralokinumab-ldrm to include children aged 12 to 17 years with moderate to severe atopic dermatitis not adequately controlled with topical therapies, according to a press release from Leo Pharma.

Tralokinumab at doses of 150 mg or 300 mg was associated with improvements over placebo in a number of efficacy outcomes at 16 weeks and 52 weeks in adolescents with moderate to severe atopic dermatitis, according to a study.

Tralokinumab, a high-affinity monoclonal antibody that specifically neutralizes interleukin-13, improved microbial diversity and reduced Staphylococcus aureus among patients with moderate to severe atopic dermatitis, according to a study.

The results of pooled safety data for Adbry showed positive effects in the prolonged treatment of moderate to severe atopic dermatitis, according to a study.